Pfizer Reports Results of Clostridioides Difficile Vaccine in P-III (CLOVER) Trial for the Prevention of C. Difficile Infection
- The P-III (CLOVER) trial evaluates C. difficile vaccine vs PBO in 17500 adults aged ≥50yrs. with CDI with a high risk of CDI in a proximal time frame to receive the primary vaccine series
- The trial did not meet its pre-specified 1EPs of prevention of primary CDI & 2EPs include a favorable benefit in reducing CDI severity, vaccine efficacy (100%), median CDI duration (1 vs 4days) & mean duration (3 vs 16days), 75% & 80% reduction in disease episode, was well tolerated with a favorable safety profile
- Additionally, vaccine efficacy in 1EPs (28.6% & 31%), following 2nd & 3rd dose. For all CDI cases @14 days post dose 3, vaccine efficacy (49%/ 47%/ 31%) @~12/24mos. & at final analysis
Ref: Pfizer | Image: Pfizer
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.